top of page

A Promising Step Forward in Pancreatic Cancer Treatment: Personalized Vaccines Show Potential

At Science4Seniors we strive to take rigorous research published in Scientific Journals and make the core information accessible to all. If you want to support us please like and follow us on Facebook.

 

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a high mortality rate, claiming the lives of 88% of patients. However, recent advancements in immunotherapy have shed light on a potential treatment approach that harnesses the power of the immune system to target the cancer cells. In a groundbreaking phase I trial, researchers explored the use of personalized neoantigen vaccines in combination with immunotherapy and chemotherapy to combat PDAC.



Personalized Neoantigen Vaccines: The trial focused on a novel vaccine called autogene cevumeran, which is created using uridine mRNA-lipoplex nanoparticles. These nanoparticles are synthesized in real time from surgically removed PDAC tumors, allowing for the development of a personalized vaccine tailored to each patient's specific mutations. This approach takes advantage of the presence of mutation-derived T cell neoantigens in PDAC, making them suitable targets for vaccines.



Treatment Approach: The treatment regimen consisted of three main components: atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (administered with a maximum of 20 neoantigens per patient), and a modified version of a four-drug chemotherapy regimen called mFOLFIRINOX. The study enrolled 16 patients who received atezolizumab and autogene cevumeran, followed by 15 patients who received mFOLFIRINOX.


Promising Results: The researchers observed several promising outcomes from the trial. Autogene cevumeran was well-tolerated by patients and induced a robust immune response in a subset of individuals. Specifically, eight out of 16 patients exhibited a significant increase in neoantigen-specific T cells, with half of them targeting multiple vaccine neoantigens. Using a new mathematical strategy called CloneTrack, the researchers were able to track the expansion of T cell clones in response to the vaccine.


Further analysis revealed that vaccine-expanded T cells accounted for up to 10% of all blood T cells. These T cells exhibited long-lasting functionality and were characterized as polyfunctional neoantigen-specific effector CD8+ T cells. Importantly, patients who experienced an expansion of vaccine-specific T cells had a significantly longer median recurrence-free survival compared to those without an immune response.


The researchers also addressed concerns about immune fitness and its potential impact on treatment outcomes. They found that the immune responses generated by the personalized vaccines were not influenced by the patients' immune fitness, as demonstrated by an equivalent immune response to an unrelated mRNA vaccine against SARS-CoV-2 in both responders and non-responders.


Conclusion: The findings of this phase I trial highlight the potential of personalized neoantigen vaccines in the treatment of pancreatic ductal adenocarcinoma. The combination of atezolizumab, autogene cevumeran, and mFOLFIRINOX demonstrated significant T cell activity, leading to a correlation with delayed PDAC recurrence.

While further research and larger clinical trials are needed to validate these findings, this study offers hope for the future of pancreatic cancer treatment. The ability to develop personalized vaccines based on individual tumor mutations holds immense potential for improving patient outcomes and survival rates. By harnessing the power of the immune system, we may be one step closer to effectively combating this deadly disease.



It is important to remember that this study represents a significant milestone, but there is still much work to be done. The field of immunotherapy is rapidly evolving, and ongoing research will continue to explore the potential of personalized vaccines and combination therapies in the fight against pancreatic cancer.

From:https://www.nature.com/articles/s41586-023-06063-y




3 views0 comments
bottom of page